Lupin has won the M&A and Business Expansion awards in the 2025 Pharmaceutical Technology Excellence Awards, recognizing the company’s strategic expansion in Europe and commitment to addressing unmet patient needs through specialty medicines.
The company won the M&A – Portfolio Expansion award for using targeted acquisitions to create a scalable European platform that enhances portfolio quality and breadth. It also received the Business Expansion – Specialty ScaleUp award for systematically strengthening its specialty capabilities in key EU markets, enabling efficient growth across eyecare and related businesses. Both these awards assume significance as Lupin strengthens its presence and offerings across Europe.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Strategic portfolio expansion through focused M&A
Over the past three years, Lupin has strategically shifted its European business toward specialty medicines through targeted acquisitions. The main highlight is the 2025 agreement to acquire VISUfarma, a pan-European ophthalmology firm that offers over 60 branded eye-health products and operates commercially in Italy, the UK, Spain, Germany and France. This acquisition will provide Lupin with direct access to comprehensive eyecare segments, including dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and targeted nutraceuticals. Lupin is expanding its European specialty portfolio through strategic acquisitions, including Medisol SAS in France and Sanofi brands such as Aarane in Germany and Nalcrom in Canada and the Netherlands.
Building sustainable specialty infrastructure
This approach creates operational synergies by leveraging shared commercial, medical, market access and pharmacovigilance structures across European entities. The strategy focuses on direct commercial capabilities rather than third-party partnerships, creating shorter pathways between treatments and patients while supporting comprehensive discussions about outcomes and healthcare value with payers.
“Visufarma’s acquisition reinforces our commitment to delivering innovative medicines to patients and communities worldwide. This strategic move expands our footprint in Europe and strengthens Lupin’s specialty franchise in Ophthalmology unlocking significant growth opportunities across the specialty segment.”
– Thierry Volle, President – EMEA and Emerging Markets
Company Profile
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Contact Details
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
E-mail: rajalakshmiazariah@lupin.com
Links
Website: https://www.lupin.com/
LinkedIn: https://www.linkedin.com/company/lupin/
X: https://x.com/LupinGlobal
Instagram: https://www.instagram.com/lupinglobal/
Facebook: https://www.facebook.com/LupinWorld/
YouTube: https://www.youtube.com/@LupinGlobal/
